FORA Capital LLC Takes $399,000 Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

FORA Capital LLC bought a new position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 6,789 shares of the company’s stock, valued at approximately $399,000.

Other large investors have also recently bought and sold shares of the company. Driehaus Capital Management LLC increased its holdings in shares of Apogee Therapeutics by 2.6% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock worth $83,338,000 after purchasing an additional 54,107 shares during the period. Perceptive Advisors LLC grew its position in Apogee Therapeutics by 2.2% during the second quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock worth $82,857,000 after buying an additional 45,241 shares in the last quarter. Vanguard Group Inc. increased its stake in Apogee Therapeutics by 60.7% during the first quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after acquiring an additional 705,795 shares during the period. Affinity Asset Advisors LLC raised its holdings in Apogee Therapeutics by 41.2% in the 2nd quarter. Affinity Asset Advisors LLC now owns 836,283 shares of the company’s stock valued at $32,908,000 after acquiring an additional 244,190 shares in the last quarter. Finally, Waypoint Capital Advisors LLC bought a new stake in shares of Apogee Therapeutics in the 3rd quarter worth approximately $36,835,000. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $87.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday, November 12th. Guggenheim lifted their target price on shares of Apogee Therapeutics from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics currently has an average rating of “Buy” and an average target price of $83.50.

Apogee Therapeutics Stock Up 1.0 %

Shares of Apogee Therapeutics stock opened at $45.15 on Friday. Apogee Therapeutics, Inc. has a 12-month low of $17.17 and a 12-month high of $72.29. The stock has a market capitalization of $2.03 billion, a P/E ratio of -18.66 and a beta of 2.93. The company has a 50-day simple moving average of $53.67 and a 200 day simple moving average of $48.51.

Insiders Place Their Bets

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $56.23, for a total value of $2,249,200.00. Following the completion of the transaction, the chief executive officer now owns 1,354,487 shares in the company, valued at approximately $76,162,804.01. The trade was a 2.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Carl Dambkowski sold 6,665 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $47.56, for a total value of $316,987.40. Following the sale, the insider now owns 280,793 shares in the company, valued at $13,354,515.08. The trade was a 2.32 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 114,995 shares of company stock valued at $6,128,295. 36.10% of the stock is currently owned by insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.